Enoximone

Enoximone is an inotropic drug used in heart failure to increase the force of heart contraction and the ejection of blood from the heart.

Enoxymon improves myocardial contractile function by increasing the intracellular concentration of cAMP and calcium in cardiomyocytes. This leads to an increase in the force of heart contractions and stroke volume of the heart.

Enoxymon is prescribed to patients with chronic heart failure who, despite taking cardiac glycosides and diuretics, retain severe signs of circulatory failure.

The medicine is administered intravenously as a solution. The dose of enoxymon is selected individually depending on the patient’s condition.

Enoxymon is marketed under the trade name Perfan. It is well tolerated by most patients, but can sometimes cause side effects such as arterial hypotension, headache, and nausea.

Enoxymon is an inotropic drug used for heart failure. It increases the force of heart contractions, which helps increase the output of blood from the heart and improve blood circulation.

Enoxymon is prescribed by injection and has the trade name Perfan. The drug is administered intravenously or intramuscularly, and its effect can last up to several hours.

When using enoxymone, it is important to consider possible side effects such as tachycardia, increased blood pressure, arrhythmia, headache and dizziness. Caution should also be exercised when using the drug in patients with heart disease or high blood pressure.

However, enoxymone is effective in improving circulation in heart failure and may be a useful adjunct to primary treatment.

Enoxymone is a medicinal compound of animal origin that is used to help with the development of heart failure, which is a consequence of coronary heart disease. The use of Enoksimon helps to increase contraction of the heart muscle and improve blood circulation. Enoximonia has an effect only on the heart, without having a significant effect on the vascular system.

Enoxymone is used topically, intravenously or as a powder suspension. Inhalation for lung replacement therapy is used in the medical staff's office. They are available worldwide as over-the-counter and prescription medications. The recommended dose is 2.5 to 5 mg/kg of patient weight, which is approximately half the dose of standard medicine. To monitor effectiveness, you can use contraction speed or lung filling, which are characterized by an increase in cardiac output (the amount of blood that the heart pumps into the bloodstream). After initial use, Enoxymones may be used to reduce the dose and gradually achieve the appropriate treatment goal. It may be necessary to complete only one course to test the effectiveness of enoxymony, 3 weeks after starting therapy. Perfan has a risk of developing arrhythmia and can lead to dry mouth, dizziness, nausea, and headache.